Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Panbela Therapeutics, Inc. (PBLA)
:PBLA
Holding PBLA?
Track your performance easily
PBLA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.30 - $7.80
Previous CloseN/A
Volume4.43K
Average Volume (3M)19.53K
Market Cap
$1.87M
Enterprise Value$7.98M
Total Cash (Recent Filing)$438.00K
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.09
Next Earnings
Mar 20, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-32.52
Shares Outstanding4,854,831
10 Day Avg. Volume18,796
30 Day Avg. Volume19,530
Standard Deviation0.33
R-Squared0.02
Alpha-0.12
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market Cap4.27
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.29
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Panbela Therapeutics News
PremiumCompany Announcements
Panbela Therapeutics Announces Q3 2024 Financial Results
PremiumPre-Earnings
Is PBLA a Buy, Before Earnings?
Ownership Overview
0.53%
Insiders
―
Mutual Funds
― Other Institutional Investors
99.47% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PBLA FAQ
What was Panbela Therapeutics, Inc.’s price range in the past 12 months?
Panbela Therapeutics, Inc. lowest stock price was $0.30 and its highest was $7.80 in the past 12 months.
What is Panbela Therapeutics, Inc.’s market cap?
Panbela Therapeutics, Inc.’s market cap is $1.87M.
When is Panbela Therapeutics, Inc.’s upcoming earnings report date?
Panbela Therapeutics, Inc.’s upcoming earnings report date is Mar 20, 2025 which is in 60 days.
How were Panbela Therapeutics, Inc.’s earnings last quarter?
Panbela Therapeutics, Inc. released its earnings results on Nov 14, 2024. The company reported -$1.48 earnings per share for the quarter, beating the consensus estimate of -$1.63 by $0.15.
Is Panbela Therapeutics, Inc. overvalued?
According to Wall Street analysts Panbela Therapeutics, Inc.’s price is currently Overvalued.
Does Panbela Therapeutics, Inc. pay dividends?
Panbela Therapeutics, Inc. does not currently pay dividends.
What is Panbela Therapeutics, Inc.’s EPS estimate?
Panbela Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Panbela Therapeutics, Inc. have?
Panbela Therapeutics, Inc. has 4,854,831 shares outstanding.
What happened to Panbela Therapeutics, Inc.’s price movement after its last earnings report?
Panbela Therapeutics, Inc. reported an EPS of -$1.48 in its last earnings report, beating expectations of -$1.63. Following the earnings report the stock price went up 6.667%.
Which hedge fund is a major shareholder of Panbela Therapeutics, Inc.?
Currently, no hedge funds are holding shares in PBLA
---
Company Description
Panbela Therapeutics, Inc.
Sun BioPharma Inc. is a clinical-stage drug development company, which engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The company was founded by Michael Cullen and Thomas Neenan on September 21, 2011 and is headquartered in Waconia, MN.
---
PBLA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive developments in clinical trials and strategic investments, balanced by financial challenges and cash flow concerns. The strategic investment from Nant Capital and progress in clinical trials were notable positives, but the financial challenges indicate ongoing risks.Read More>---
Technical Analysis
Aditxt, Inc.
―
Cyclacel Pharmaceuticals
―
Genprex
―
SELLAS Life Sciences Group
―
Crinetics Pharmaceuticals
―
Voyager Therapeutics
―
---